For the Inventor, By the Inventor

Enter assignee name

Irvine, CA, United States of America

Spectrum Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 38

% Expired Patents = 34.2

CIPO Patents = 8

EPO Patents = 13

Trademarks = 7

Forward Citations = 109

Loading Chart...

Loading Chart...

43 inventors (with patents filed for the assignee):

Guru Reddy (13 out of 14 patents)

Luigi Lenaz (12 out of 13 patents)

Anil Gulati (8 out of 23 patents)

4. David B Fick (6 out of 13 patents)

5. Alvin Jerald Glasky (6 out of 20 patents)

6. Gajanan Bhat (5 out of 5 patents)

7. Shanta Chawla (5 out of 5 patents)

8. Bastiaan Nuijen (5 out of 10 patents)

9. Ernie Pfadenhauer (5 out of 5 patents)

10. David R Helton (5 out of 16 patents)

11. Edward A Schauer (4 out of 7 patents)

12. Jos H Beijnen (4 out of 4 patents)

13. Eun Jung Kim (3 out of 24 patents)

14. Rudi E Moerck (3 out of 50 patents)

15. Timothy Malcome Spitler (3 out of 16 patents)

Core Competencies:

G-CSF Protein Complex

Eflapegrastim

Bladder Cancer

Thioxanthone

Tetrahydroindolone

Radiation Therapy

LHRH Antagonists

Vincristine

Quinazoline Compounds

Medical Compositions

Cognitive Disorders

Rare Earth Metals

38 patents: Sort by Forward Citations

1. 12350315 - Methods of treating neutorpenia using G-CSF protein complex (2025-07-08),

2. 12318430 - Methods of treating neutorpenia using G-CSF protein complex (2025-06-03),

3. 12202871 - Methods of treatment using G-CSF protein complex (2025-01-21),

4. 12171804 - Methods of treating chemotherapy induced neutropenia using fixed doses of eflapegrastim (2024-12-24),

5. 11883402 - Crystalline forms of a quinazoline compound and its hydrochloride salts (2024-01-30),

6. 11684655 - Methods of treating neutorpenia using G-CSF protein complex (2023-06-27),

7. 11267858 - Methods of treatment using G-CSF protein complex (2022-03-08),

8. 10022421 - Treatment of primary and metastatic carcinoma (2018-07-17),

9. 9801874 - Method for the preparation of liposome encapsulated vincristine for therapeutic use (2017-10-31),

10. 9713616 - Pharmaceutical compositions comprising L-leucovorin (2017-07-25),

11. 9511091 - Rare earth metal compounds, methods of making, and methods of using the same (2016-12-06),

12. 9308235 - Treatment of primary and metastatic carcinoma (2016-04-12),

13. 9295666 - Bladder cancer treatment and methods (2016-03-29),

14. 9000031 - Thioxanthone-based autophagy inhibitor therapies to treat cancer (2015-04-07),

15. 8961917 - Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use (2015-02-24),

Company Overview

Spectrum Pharmaceuticals, Inc. is a biotechnology company based in Irvine, California, focused on the development and commercialization of innovative therapies for cancer. The company specializes in targeted treatments and has a robust pipeline aimed at addressing unmet medical needs in oncology. Spectrum is committed to advancing its research in various cancer indications, leveraging cutting-edge science and technology to improve patient outcomes and enhance quality of life for those affected by cancer.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

38 Patents

#91 in Irvine, CA

#2,138 in California

#9,051 in US

#17,897 in the World

Irvine, CA, United States of America

Spectrum Pharmaceuticals, Inc.

Forward Citations = 109

43 inventors:

Guru Reddy (13 out of 14 patents)

Luigi Lenaz (12 out of 13 patents)

Anil Gulati (8 out of 23 patents)

4. David B Fick (6 out of 13 patents)

5. Alvin Jerald Glasky (6 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Spectrum Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/spectrum-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…